Mr. Chair, at the time that discussions were taking place for vaccine acquisitions, I was not in the role of president of the National Research Council, although I can say that in the circumstances that the minister described, there was certainly discussion of whether the NRC could produce...a technology transfer could take place at the NRC, for example, for the AstraZeneca candidate, and also, of course, also with Novavax, which now of course has borne fruit into an MOU that we have now signed with Novavax. Those were definitely ongoing conversations.
On February 22nd, 2021. See this statement in context.